Dr. Agarwal’s Health Care Limited, a prominent name in the eye care industry, is set to launch its Initial Public Offering (IPO) on January 29, 2025. This article provides a comprehensive overview of the company’s background, IPO specifics, financial health, strengths, risks, and other pertinent details to assist potential investors in making informed decisions.

Company Overview

Established in 2010, Dr. Agarwal’s Health Care Limited offers a wide array of eye care services, including cataract and refractive surgeries, consultations, diagnostics, non-surgical treatments, and the sale of optical products and eye care pharmaceuticals. As of March 31, 2024, the company operates 180 facilities across India and has expanded internationally with 15 centers in nine African countries. In the fiscal year 2024, the company served 2.13 million patients and performed over 220,000 surgeries.

IPO Timeline

• Issue Opening Date: January 29, 2025
• Issue Closing Date: January 31, 2025
• Basis of Allotment: February 3, 2025
• Initiation of Refunds: February 4, 2025
• Credit of Shares to Demat: February 4, 2025
• Listing Date: February 5, 2025

Price Band

The IPO price band is set between ₹382 to ₹402 per equity share. Investors can bid within this range during the subscription period.

Lot Size

The minimum lot size is 35 shares, requiring a minimum investment of ₹14,070. Retail investors can apply for up to 13 lots, totaling 490 shares, amounting to ₹196,980.

Key Dates

Financials

The company’s financial performance over the past three fiscal years is as follows:

Note: Data sourced from the company’s financial reports.

Strengths

• Comprehensive Service Portfolio: Offers a wide range of eye care services and products, catering to diverse patient needs.
• Extensive Network: Operates 180 facilities across India and 15 international centers, ensuring broad accessibility.
• Experienced Team: Employs 667 doctors as of March 31, 2024, providing expert care to patients.

Risks

• Revenue Dependency: A significant portion of revenue is derived from surgical procedures; any decline in patient footfall or surgical demand could impact financial performance.
• Reputation Management: The company’s success is closely tied to its reputation; any negative publicity or service quality issues could adversely affect business.
• Talent Retention: The ability to attract and retain skilled medical professionals is crucial; high turnover or inability to recruit qualified staff may impact operations.

IPO Anchor Investors Details

As of now, specific details regarding anchor investors have not been publicly disclosed. Investors are advised to monitor official communications from the company for updates.

IPO Promoter Holding

IPO Grey Market Premium (GMP)

As of January 25, 2025, the shares of Dr. Agarwal’s Health Care Limited are trading at a premium of ₹55 in the grey market. Investors should note that GMP is subject to change and may not accurately reflect the stock’s performance upon listing.

Final Thoughts

Dr. Agarwal’s Health Care Limited’s upcoming IPO presents an opportunity to invest in a leading player in the eye care sector with a strong track record and extensive network. Potential investors should carefully consider the company’s financial performance, strengths, and associated risks before making investment decisions. It is advisable to consult with financial advisors and review the official prospectus for detailed information.